Lobbying client
EVERGLADE PHARMACEUTICALS, LLC
Development and manufacturing of essential medicines.
Filings
6
Filed by
1
Reported in-house
—
Reported by firms
—
Reported lobbying by year
The larger of in-house and firm-reported each year, $ thousands
2021 to 2022
Filings
6 filings, newest first.
| Filing | Filed by | Amount |
|---|---|---|
|
1st Quarter - Termination 1st Quarter 2022
|
FORBES-TATE | — reported |
|
4th Quarter - Report 4th Quarter 2021
|
FORBES-TATE | — reported |
|
3rd Quarter - Report 3rd Quarter 2021
|
FORBES-TATE | — reported |
|
2nd Quarter - Report 2nd Quarter 2021
|
FORBES-TATE | — reported |
|
1st Quarter - Report 1st Quarter 2021
|
FORBES-TATE | — reported |
|
Registration 1st Quarter 2021
|
FORBES-TATE | — reported |
Filed by
Each firm that has reported for this client, and the client itself where it lobbies in-house, with the reports filed and the amounts they disclose.
| Firm | Reports | Amount |
|---|---|---|
| FORBES-TATE | 5 | — |
Issues lobbied
How many report sections named each issue, counting the current version of each report.
| Issue | Code | Mentions |
|---|---|---|
| Manufacturing | MAN | 6 |
| Health Issues | HCR | 6 |
Bills named in its filings
Bill numbers found in the filers' descriptions, most often named first.
| Bill | Congress | Times named |
|---|---|---|
| H.R. 1319 | 117th | 10 |
From reports filed under the Lobbying Disclosure Act. Firms report what each client paid them; an organisation lobbying for itself reports its own expenses. Amounts count the current version of each report once.